Key Stats for Vertex Stock
- 52-Week Range: $362.5 to $510.8
- Current Price: $438.7
- Street High Target: $641
What Happened?
Vertex Pharmaceuticals (VRTX), the dominant force in cystic fibrosis drug development now accelerating into kidney disease, secured dual FDA label expansions on April 1 for its CF treatments ALYFTREK and TRIKAFTA, pushing combined patient eligibility to roughly 95% of all U.S. CF patients while its stock sits at $438.30 against a 52-week high of $510.77 as Wall Street prices in a pipeline that just delivered landmark kidney data.
The March 9 RAINIER Phase 3 interim read on povetacicept, a dual-mechanism injectable biologic targeting the underlying B-cell drivers of IgA nephropathy (a progressive kidney disease affecting 330,000 patients in the U.S. and Europe), delivered a 52% reduction in urinary protein at 36 weeks and met every primary and secondary endpoint with no serious adverse events linked to the drug, prompting Vertex to complete its FDA approval filing by end of March.
Fueling the investment case, Vertex’s non-CF product revenue is targeting $500 million or more in 2026, more than tripling 2025’s combined contribution from CASGEVY (its gene therapy for sickle cell disease) and JOURNAVX (its non-opioid painkiller), while JOURNAVX prescriptions alone are guided to exceed 1.65 million after crossing 550,000 in its first full year, a ramp that compares favorably to first-year launch trajectories for branded specialty drugs in analogous pain categories.
Vertex CEO and President Reshma Kewalramani stated on the Q4 2025 earnings call that “2026 priorities include expanding leadership in CF, accelerating adoption of CASGEVY, growing JOURNAVX, both in prescriptions and revenue and advancing the emerging renal franchise, starting with pove in IgAN,” framing the kidney franchise as the company’s fourth commercial vertical alongside CF, gene therapy, and pain.
Vertex enters its next phase with TRIKAFTA’s core patent protected through 2037, a $12.3 billion cash position backing five active Phase 3 programs, JOURNAVX’s salesforce doubling to 300 reps in Q2 2026, and povetacicept positioned for potential accelerated approval in H2 2026 before expanding into membranous nephropathy and myasthenia gravis, a pipeline sequence that could rival the scale of its CF franchise within a decade.
Wall Street’s Take on VRTX Stock
The April 1 FDA label expansions for ALYFTREK and TRIKAFTA, which extend CFTR modulator eligibility (drugs that restore defective protein function in cystic fibrosis patients) to roughly 95% of U.S. CF patients, directly expand the addressable base for Vertex’s most durable revenue stream ahead of a year where four commercial franchises are simultaneously scaling.
Revenue is guided to $13.03 billion in FY2026, up 8.6% from $12.0 billion in FY2025, with the JOURNAVX salesforce doubling to 300 reps in Q2 and CASGEVY’s patient pipeline providing clear infusion visibility into the back half of the year.
Thirty-one analysts currently cover VRTX with 22 buys, 5 outperforms, 4 holds, and just 2 sells, putting the mean price target at $547.72, implying 24.8% upside from $438.71 as the Street prices in povetacicept’s potential accelerated approval in H2 2026.
The analyst target range spans $330 to $641, where the low reflects a scenario of povetacicept approval delays and gross-to-net pressure on JOURNAVX, while the high of $641 implies successful IgAN launch momentum and DPN Phase 3 data in 2027 confirming JOURNAVX as a second multibillion-dollar franchise.
What Does the Valuation Model Say?
The TIKR model projects a $827.11 mid-case price target by December 31, 2030, underpinned by 10.5% revenue CAGR through FY2030 driven by povetacicept’s renal franchise expansion, JOURNAVX’s prescription tripling in FY2026, and CASGEVY’s global infusion ramp across four disease areas.
At $438.71, VRTX trades at roughly 22.9x FY2026E normalized EPS of $19.16, sitting near its five-year historical average forward P/E of approximately 22x, yet the TIKR mid-case models 11.9% EPS CAGR through FY2030 against a pipeline catalyst sequence that has materially de-risked since March 9 — VRTX stock is fairly valued today, but the compounding runway makes the current entry unusually attractive relative to the forward earnings trajectory.
The TIKR model’s $827.11 target is anchored to FCF inflecting from $3.19 billion in FY2025 to $4.99 billion in FY2026, a 56.3% jump driven by JOURNAVX gross-to-net normalization and CASGEVY scaling, two confirmed operational developments already underway.
CEO Reshma Kewalramani’s framing of povetacicept as a “pipeline in a product” across IgAN, membranous nephropathy, and myasthenia gravis signals that the renal franchise IRR is materially understated by models pricing only the IgAN indication.
The primary model risk is povetacicept’s FDA accelerated approval being delayed beyond H2 2026, which would compress the renal revenue ramp and pressure the FY2027E revenue estimate of $14.36 billion.
Inaxaplin’s AMPLITUDE interim readout, expected late 2026 or early 2027, is the next binary event to watch, with a positive eGFR stabilization result representing the confirmation that Vertex’s renal franchise can ultimately rival its CF business in scale.
Should You Invest in Vertex Pharmaceuticals Incorporated?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up VRTX stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Vertex Pharmaceuticals Incorporated alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze VRTX stock on TIKR for Free →
